Skip to main content
SpringerLink
Log in

Intraokulare Triamcinolongabe bei diffusem diabetischen Makulaödem

  • Originalien
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Ziel der Studie war zu untersuchen, ob eine intravitreale Injektion von Triamcinolon Acetonid sich auf den Visus von Patienten mit diffusem diabetischen Makulaödem auswirkt.

Patienten und Methode

Die prospektive, klinisch interventionelle, nicht kontrollierte Studie umfasste 32 Augen (26 Patienten) mit diffusem diabetischen Makulaödem, die eine intravitreale Injektion von 25 mg kristallinem Triamcinolon Acetonid erhielten. Der Ausgangsvisus lag bei 0,12±0,08 (Min.-Max.: 0,03 – 0,3; Median 0,1). Die Nachbeobachtungsdauer betrug 6,8±4,3 Monate.

Ergebnisse

Der Visus stieg signifikant an auf 0,17±0,11 (Min.-Max.: 0,03 – 0,4; Median 0,125) nach 4 Wochen (p=0,009) und erreichte 8 Wochen nach der Injektion ein mittleres Maximum von 0,20±0,14 (Min.-Max.: 0,03–0,6; Median 0,16; p=0,006). Später sank der Visus langsam wieder ab, lag jedoch bis 6 Monate postoperativ signifikant über dem Ausgangswert. Insgesamt zeigten 26 Augen (81,3%) eine Visusverbesserung, 10 Augen (31,2%) entwickelten eine okuläre Hypertension.

Schlussfolgerungen

Eine intravitreale Injektion von Triamcinolon Acetonid ist möglicherweise eine therapeutische Option in der Behandlung des diffusen diabetischen Makulaödems.

Abstract

Background

The aim of the study was to evaluate the effect of an intravitreal injection of triamcinolone acetonide on the visual acuity of patients suffering from diffuse diabetic macular edema.

Patients and methods

The prospective, clinically interventional, uncontrolled study included 32 eyes (26 patients) with diffuse diabetic macular edema and received an intravitreal injection of 25 mg triamcinolone acetonide. Visual acuity was 0.12±0.08 (min.–max. 0.03–0.3; median 0.1) at baseline. Mean follow-up was 6.8±4.3 months.

Results

Visual acuity increased to 0.17±0.11 (min.–max.: 0.03–0.4; median 0.125) after 4 weeks (p=0.009) and reached a mean maximum of 0.20±0.14 (min.–max.: 0.03–0.5; median 0.16) after 8 weeks (p=0.006). Later, visual acuity showed a slow decrease, but was significantly higher than at baseline up to 6 months postoperatively and 26 eyes (81.3%) gained in visual acuity. Ten eyes (31.2%) developed steroid-induced secondary ocular hypertension.

Conclusion

An intravitreal injection of 25 mg of triamcinolone acetonide may be an option in the treatment of diffuse diabetic macular edema.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Challa JK, Gillies MC, Penfold PL et al. (1998) Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26:277–281

    CAS  PubMed  Google Scholar 

  2. Degenring RF, Jonas JB (2003) Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis. Br J Ophthalmol 87:361

    Google Scholar 

  3. Degenring RF, Kreissig I, Jonas JB (2002) Fluorescein angiography after intravitreal Injection of Triamcinolone Acetonide as treatment of diffuse diabetic macular edema. Jahrestagung der Association for Research in Vision and Ophthalmology (ARVO), Fort Lauderdale. Invest Ophthalmol Vis Sci 43:Abstract 3473

    Google Scholar 

  4. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology 94:761–774

    PubMed  Google Scholar 

  5. Gandorfer A, Messmer EM, Ulbig MW, Kampik A (2000) Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina 20:126–133

    CAS  PubMed  Google Scholar 

  6. Guyer DR, D’Amico DJ, Smith CW (1992) Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 113:652–656

    Google Scholar 

  7. Heffernan JT, Futterman S, Kalina RE (1978) Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. Invest Ophthalmol Vis Sci 17:565–568

    CAS  PubMed  Google Scholar 

  8. Hida T, Chandler D, Arena JE, Machemer R (1986) Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 101:190–195

    CAS  PubMed  Google Scholar 

  9. Jonas JB (2002) Concentration of intravitreally injected triamcinolone acetonide in aqueous humour. Br J Ophthalmol 86:1066

    Article  Google Scholar 

  10. Jonas JB, Degenring R (2002) Intravitreale Injektion von kristallinem Triamcinolon Acetonid als Therapie des diffusen diabetischen Makulaödems. Klin Monatsbl Augenheilkd 219:429–432

    Article  PubMed  Google Scholar 

  11. Jonas JB, Kreissig I, Degenring RF (2002) Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 240:782–783

    Google Scholar 

  12. Jonas JB, Kreissig I, Degenring RF (2003) Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 87:24–27

    Google Scholar 

  13. Jonas JB, Kreissig I, Söfker A, Degenring RF (2003) Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 121:57–61

    CAS  PubMed  Google Scholar 

  14. Joussen AM, Poulaki V, Mitsiades N et al. (2002) Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438–440

    CAS  PubMed  Google Scholar 

  15. Klein RB, Klein BE, Moss SE, Cruickshanks KJ (1995) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long- term incidence of macular edema. Ophthalmology 102:7–16

    CAS  PubMed  Google Scholar 

  16. Lewis H, Schachat AP, Haimann MH et al. (1990) Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 97:503–510; discussion 510–511

    PubMed  Google Scholar 

  17. Machemer R, Sugita G, Tano Y (1979) Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc 77:171–180

    CAS  PubMed  Google Scholar 

  18. Martidis A, Duker JS, Greenberg PB et al. (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–927

    Article  PubMed  Google Scholar 

  19. Olk RJ (1986) Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology 93:938–950

    CAS  PubMed  Google Scholar 

  20. Roth DB, Chieh J, Spirn M et al. (2003) Sterile endophthalmitis associated with intravitreal triamcinolone injection [abstract 3223] Jahrestagung der Association for Research in Vision and Ophthalmology (ARVO), Ft. Lauderdale. 2003 Annual Meeting Abstract and Program Planner (on CD-ROM)

  21. Schatz H, Madeira D, McDonald HR, Johnson RN (1991) Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol 109:1549–1551

    CAS  Google Scholar 

  22. Schindler RH, Chandler D, Thresher R, Machemer R (1982) The clearance of intravitreal triamcinolone acetonide. Am J Ophthalmol 93:415–417

    CAS  PubMed  Google Scholar 

  23. Wilson DJ, Finkelstein D, Quigley HA, Green WR (1988) Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol 106:100–105

    PubMed  Google Scholar 

  24. Young S, Larkin G, Branley M, Lightman S (2001) Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 29:2–6

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fakultät für Klinische Medizin Mannheim der Ruprecht-Karls-Universität Heidelberg, Universitäts-Augenklinik Mannheim

    R. F. Degenring, I. Kreissig & J. B. Jonas

  2. Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1–3, 68167 , Mannheim

    R. F. Degenring

Authors
  1. R. F. Degenring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. Kreissig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. B. Jonas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. F. Degenring.

Additional information

Vortrag gehalten auf der 100. Jahrestagung der Deutschen Ophthalmologischen Gesellschaft, 26.–29.09.02, Berlin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Degenring, R.F., Kreissig, I. & Jonas, J.B. Intraokulare Triamcinolongabe bei diffusem diabetischen Makulaödem. Ophthalmologe 101, 251–254 (2004). https://doi.org/10.1007/s00347-003-0862-7

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-003-0862-7

Schlüsselwörter

Keywords

Search

Navigation